BR9711411A - Processo para a profilaxia e/ou tratamento da hiperlipidemia hipercolesterolemia ou hipertrigliceridemia uso de um composto e composicao farmac-utica - Google Patents

Processo para a profilaxia e/ou tratamento da hiperlipidemia hipercolesterolemia ou hipertrigliceridemia uso de um composto e composicao farmac-utica

Info

Publication number
BR9711411A
BR9711411A BR9711411A BR9711411A BR9711411A BR 9711411 A BR9711411 A BR 9711411A BR 9711411 A BR9711411 A BR 9711411A BR 9711411 A BR9711411 A BR 9711411A BR 9711411 A BR9711411 A BR 9711411A
Authority
BR
Brazil
Prior art keywords
compound
hypertriglyceridemia
prophylaxis
treatment
pharmaceutical composition
Prior art date
Application number
BR9711411A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Finian Kelly
Steph Paul Jones
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of BR9711411A publication Critical patent/BR9711411A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fats And Perfumes (AREA)
  • Analogue/Digital Conversion (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR9711411A 1996-09-25 1997-09-15 Processo para a profilaxia e/ou tratamento da hiperlipidemia hipercolesterolemia ou hipertrigliceridemia uso de um composto e composicao farmac-utica BR9711411A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619961.7A GB9619961D0 (en) 1996-09-25 1996-09-25 Medical treatment
PCT/EP1997/005040 WO1998013034A1 (en) 1996-09-25 1997-09-15 Use of sibutramine analogues to lower lipid levels

Publications (1)

Publication Number Publication Date
BR9711411A true BR9711411A (pt) 1999-08-17

Family

ID=10800447

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711411A BR9711411A (pt) 1996-09-25 1997-09-15 Processo para a profilaxia e/ou tratamento da hiperlipidemia hipercolesterolemia ou hipertrigliceridemia uso de um composto e composicao farmac-utica

Country Status (26)

Country Link
US (1) US6187820B1 (enExample)
EP (1) EP0973511B1 (enExample)
JP (1) JP4143126B2 (enExample)
KR (1) KR100573333B1 (enExample)
CN (1) CN1173696C (enExample)
AT (1) ATE239459T1 (enExample)
AU (1) AU724645B2 (enExample)
BG (1) BG64472B1 (enExample)
BR (1) BR9711411A (enExample)
CA (1) CA2266378C (enExample)
CZ (1) CZ291879B6 (enExample)
DE (1) DE69721833T2 (enExample)
DK (1) DK0973511T3 (enExample)
ES (1) ES2199354T3 (enExample)
GB (1) GB9619961D0 (enExample)
HU (1) HU224711B1 (enExample)
IL (1) IL128820A (enExample)
NO (1) NO991424L (enExample)
NZ (1) NZ334550A (enExample)
PL (1) PL190017B1 (enExample)
PT (1) PT973511E (enExample)
RU (1) RU2197959C2 (enExample)
SK (1) SK284282B6 (enExample)
TR (1) TR199900648T2 (enExample)
UA (1) UA63916C2 (enExample)
WO (1) WO1998013034A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
AU3894500A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
HRP20050307A2 (en) * 2002-10-05 2006-12-31 Hanmi Pharm. Co. Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
EP1622600A1 (en) * 2003-04-28 2006-02-08 Cipla Ltd. Pharmaceutical formulation comprising anti-obesity agent and acidulant
US20050032908A1 (en) * 2003-08-04 2005-02-10 Beckman Kristen M. Methods for treating metabolic syndrome
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
KR100618176B1 (ko) 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
JP2008526836A (ja) * 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
KR20060080818A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
KR20060080817A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR100814384B1 (ko) * 2006-02-10 2008-03-18 대화제약 주식회사 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법
WO2008034142A2 (en) 2006-09-15 2008-03-20 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
WO2010082216A2 (en) * 2008-12-08 2010-07-22 Matrix Laboratories Ltd Novel salts of sibutramine and their crystal forms
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
IL128820A0 (en) 2000-01-31
EP0973511B1 (en) 2003-05-07
JP4143126B2 (ja) 2008-09-03
HUP9903823A3 (en) 2000-07-28
NO991424D0 (no) 1999-03-24
IL128820A (en) 2001-10-31
NO991424L (no) 1999-03-24
TR199900648T2 (xx) 1999-06-21
UA63916C2 (uk) 2004-02-16
AU4774197A (en) 1998-04-17
PL332367A1 (en) 1999-09-13
CA2266378A1 (en) 1998-04-02
RU2197959C2 (ru) 2003-02-10
CA2266378C (en) 2007-02-13
HU224711B1 (en) 2006-01-30
JP2001500883A (ja) 2001-01-23
NZ334550A (en) 2000-09-29
DE69721833T2 (de) 2003-12-24
ES2199354T3 (es) 2004-02-16
AU724645B2 (en) 2000-09-28
PT973511E (pt) 2003-08-29
BG103249A (bg) 1999-09-30
CN1173696C (zh) 2004-11-03
PL190017B1 (pl) 2005-10-31
GB9619961D0 (en) 1996-11-13
HUP9903823A2 (hu) 2000-06-28
KR100573333B1 (ko) 2006-04-24
SK284282B6 (sk) 2004-12-01
DE69721833D1 (de) 2003-06-12
EP0973511A1 (en) 2000-01-26
KR20000048567A (ko) 2000-07-25
CZ291879B6 (cs) 2003-06-18
US6187820B1 (en) 2001-02-13
BG64472B1 (bg) 2005-04-30
WO1998013034A1 (en) 1998-04-02
ATE239459T1 (de) 2003-05-15
CN1231605A (zh) 1999-10-13
DK0973511T3 (da) 2003-08-25
SK32099A3 (en) 1999-12-10
CZ93299A3 (cs) 2000-07-12

Similar Documents

Publication Publication Date Title
BR9711411A (pt) Processo para a profilaxia e/ou tratamento da hiperlipidemia hipercolesterolemia ou hipertrigliceridemia uso de um composto e composicao farmac-utica
BR0014293A (pt) Uso de retigabina para o tratamento de dor neuropática
ATE232720T1 (de) Adjuvans für impfstoff
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9506473A (pt) Composto processo para a preparação de compostos utilização de um composto composição farmacêutica e processo para o tratamento de infecções anti-fúngicas
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
BR9501770A (pt) Uso de um composto,composto,formulação farmacêutica e processo para preparar um composto
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
BR9505107A (pt) Composto composiçao farmacêutica processo para a preparaçao de um composto e seu uso
BR9406509A (pt) Compostos processo sua preparação uso dos mesmos composições farmaceuticas e processo para profilaxia e para tratamento terapeutico de malária e doenças causadas por leishmania toxoplasma gondil pneumocy
BR0215027A (pt) Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação
PT773022E (pt) Preparacao farmaceutica para o tratamento de rinites agudas contendo simpaticomimeticos e pantotenol e/ou acido pantotenico
BR9607346A (pt) Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
BR0113590A (pt) 7-oxo-piridopirimidinas
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
BR9600339A (pt) Compostos composições farmacêuticas processo para a preparação de um composto e uso dos mesmos
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
BR9800718A (pt) Composto esteróide composição farmacéutica uso de um composto esteróide e processo para a preparação de um estróide
BR9806102A (pt) Processo para o ajuste de uma mola de membrana.
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
BR9810387A (pt) (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica
BR9507976A (pt) Mistura fungicida processo para controlar fungos nocivos e uso de um composto
CA2262267A1 (en) Anti-migraine pharmaceutical compositions and process of using

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
B25D Requested change of name of applicant approved

Owner name: KNOLL GMBH (DE)

Free format text: ALTERADO DE: KNOLL AKTIENGESELLSCHAFT

B25A Requested transfer of rights approved

Owner name: ABBOTT GMBH (DE)

Free format text: TRANSFERIDO POR INCORPORACAO DE: KNOLL GMBH

B25D Requested change of name of applicant approved

Owner name: ABBOTT GMBH AND CO. KG (DE)

Free format text: ALTERADO DE: ABBOTT GMBH

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO DE TRANSFERENCIA NO 042395/RJ DE 31/07/2003, POR FALTA DE FUNDAMENTACAO LEGAL.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1908 DE 31/07/2007.